Skip to main navigation Skip to search Skip to main content

A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumors

  • Markman, Ben (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

SERP Reference Number: HREC/15/MH/77.
SSA Reference Number: SSA/15/MonH/68.
Monash Health HREC Ref: 15295X

StatusFinished
Effective start/end date20/12/18 → 19/12/23

Clinical Trial Phase

  • Phase I